Lynx1 Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Lynx1 Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,253,183	Closed	-$89.3M	–	21
2024 Q1	$89.3M	Sell	2,253,183 -1,560,743	-41%	-$46.1M	23.01%	1
2023 Q4	$72.7M	Buy	3,813,926 +1,409,312	+59%	+$19.6M	28.58%	1
2023 Q3	$27.5M	Sell	2,404,614 -265,858	-10%	-$3.27M	18.21%	2
2023 Q2	$27.5M	Sell	2,670,472 -465,701	-15%	-$4.2M	17.99%	3
2023 Q1	$24.2M	Buy	3,136,173 +10,000	+0.3%	+$79.7K	20.18%	1
2022 Q4	$23M	Buy	3,126,173 +69,753	+2%	+$446K	19.87%	2
2022 Q3	$22M	Buy	3,056,420 +1,129,551	+59%	+$9.31M	19.85%	2
2022 Q2	$16.4M	Buy	1,926,869 +442,176	+30%	+$3.81M	13.97%	4
2022 Q1	$13.3M	Buy	1,484,693 +222,766	+18%	+$1.93M	12.37%	3
2021 Q4	$17.5M	Buy	+1,261,927	New	+$15.6M	15.25%	3

Lynx1 Capital Management's ALPN Position: Q2 2024 in Review

Lynx1 Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 2,253,183 shares — an estimated $89.3M sold.

Lynx1 Capital Management first reported a position in ALPN in Q4 2021 and held it in 10 quarters. The position peaked at $89.3M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

Lynx1 Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
Lynx1 Capital Management sold 2,253,183 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $89.3M.
Lynx1 Capital Management first reported a position in Alpine Immune Sciences Inc in Q4 2021 and held it in 10 quarters.
Lynx1 Capital Management's Alpine Immune Sciences Inc position peaked at $89.3M in Q1 2024.
0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Lynx1 Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.